GW Pharmaceuticals plc GWPH said Monday it will obtain exclusive rights for the commercialization of Sativex in the U.K. from Bayer AG BAYRY.
Sativex is an oromucosal spray with the principal cannabinoids delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD) in a 1-to-1 ratio.
In the U.S. it is known under the name Nabiximols and is used to help treat spasticity in patients suffering from multiple sclerosis.
The spray was approved by the Medicines and Healthcare products Regulatory Agency back in 2010, and Bayer has seen controlled advertising in the U.K.
GW Pharma will obtain all duties regarding the commercialization of Sativex in the U.K., after the end of the year, and will be in a transitional period until then, according to the company.
GW Pharma’s shares were trading lower by at $100.78 at the time of publication Monday.
Related Links:
GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!